Clinical Trial Update: Phase 3 Trial in Subjects With Metastatic Melanoma Comparing 3 mg/kg Ipilimumab Versus 10 mg/kg Ipilimumab [Phase 3]

View source ↗

Summary

Phase 3 trial comparing 3 mg/kg versus 10 mg/kg ipilimumab in metastatic melanoma has been completed with results posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• ipilimumab (ipilimumab)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Melanoma | Phase 3 | Status: COMPLETED | Results posted: 2017-03-24